Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward T Ryan

Showing results (281-290 of 323) with videos related to

Pageof 33
Sort By:
Plos Neglected Tropical Diseases|April 7, 2018
Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteersKamrul Islam, Motaher Hossain, Meagan Kelly, et al.
Clinical and Vaccine Immunology : CVI|March 22, 2013
Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in BangladeshDaniel T Leung, Taher Uddin, Peng Xu, et al.
Plos Neglected Tropical Diseases|August 13, 2013
Identification of immunogenic Salmonella enterica serotype Typhi antigens expressed in chronic biliary carriers of S. Typhi in Kathmandu, NepalRichelle C Charles, Tania Sultana, Mohammad Murshid Alam, et al.
Msphere|July 7, 2021
Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139Mohammad Kamruzzaman, Meagan Kelly, Richelle C Charles, et al.
Mbio|October 26, 2022
Identifying Recent Cholera Infections Using a Multiplex Bead Serological AssayForrest K Jones, Taufiqur R Bhuiyan, Rachel E Muise, et al.
Immunity|August 14, 2020
Distinct Early Serological Signatures Track with SARS-CoV-2 SurvivalCaroline Atyeo, Stephanie Fischinger, Tomer Zohar, et al.
Nature Communications|December 12, 2025
Gut bacteria-derived sphingolipids alter innate immune responses to oral cholera vaccine antigensDenise Chac, Frederick J Heller, Hasan Al Banna, et al.
Mbio|December 9, 2025
Clinical and environmental wastewater-based bacteriophage surveillance for high-impact diarrheal diseases, including cholera, in BangladeshMarjahan Akhtar, Md Ariful Amin, Subah Nuzhat Hussain, et al.
Mbio|September 12, 2025
Human antibody targeting <i>Vibrio cholerae</i> O1 O-specific polysaccharide induces an amotile hypovirulent bacterial phenotype: mechanism of protection against choleraSmriti Verma, Murat Cetinbas, Meagan Kelly, et al.
The American Journal of Tropical Medicine and Hygiene|April 2, 2014
Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with choleraTaher Uddin, Amena Aktar, Peng Xu, et al.
Pageof 33

Showing results (281-290 of 323) with videos related to

Sort By:
Pageof 33
Plos Neglected Tropical Diseases|April 7, 2018
Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteersKamrul Islam, Motaher Hossain, Meagan Kelly, et al.
Clinical and Vaccine Immunology : CVI|March 22, 2013
Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in BangladeshDaniel T Leung, Taher Uddin, Peng Xu, et al.
Plos Neglected Tropical Diseases|August 13, 2013
Identification of immunogenic Salmonella enterica serotype Typhi antigens expressed in chronic biliary carriers of S. Typhi in Kathmandu, NepalRichelle C Charles, Tania Sultana, Mohammad Murshid Alam, et al.
Msphere|July 7, 2021
Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139Mohammad Kamruzzaman, Meagan Kelly, Richelle C Charles, et al.
Mbio|October 26, 2022
Identifying Recent Cholera Infections Using a Multiplex Bead Serological AssayForrest K Jones, Taufiqur R Bhuiyan, Rachel E Muise, et al.
Immunity|August 14, 2020
Distinct Early Serological Signatures Track with SARS-CoV-2 SurvivalCaroline Atyeo, Stephanie Fischinger, Tomer Zohar, et al.
Nature Communications|December 12, 2025
Gut bacteria-derived sphingolipids alter innate immune responses to oral cholera vaccine antigensDenise Chac, Frederick J Heller, Hasan Al Banna, et al.
Mbio|December 9, 2025
Clinical and environmental wastewater-based bacteriophage surveillance for high-impact diarrheal diseases, including cholera, in BangladeshMarjahan Akhtar, Md Ariful Amin, Subah Nuzhat Hussain, et al.
Mbio|September 12, 2025
Human antibody targeting <i>Vibrio cholerae</i> O1 O-specific polysaccharide induces an amotile hypovirulent bacterial phenotype: mechanism of protection against choleraSmriti Verma, Murat Cetinbas, Meagan Kelly, et al.
The American Journal of Tropical Medicine and Hygiene|April 2, 2014
Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with choleraTaher Uddin, Amena Aktar, Peng Xu, et al.
Pageof 33